Abstract: Purified BMP-11 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the proteins may be useful for the induction of bone, cartilage and/or other connective tissue.
Abstract: Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
March 4, 1991
Date of Patent:
August 13, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki Rosen
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
Type:
Grant
Filed:
February 18, 1998
Date of Patent:
July 2, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
Abstract: Methods are disclosed for inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, comprising administering to a subject a therapeutically effective amount of a PSGL antagonist.
Type:
Application
Filed:
July 12, 2001
Publication date:
May 16, 2002
Applicant:
Genetics Institute, Inc.
Inventors:
Narasimhaswamy Manjunath, Ulrich Hans von Andrian
Abstract: Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of factor IX and formulations of factor IX suitable for storage and administration.
Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Type:
Grant
Filed:
March 10, 1995
Date of Patent:
March 5, 2002
Assignees:
Genetics Institute, Inc., The Regents of the University of Michigan
Inventors:
Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
Abstract: Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, inhibitors of binding of human IL-11 and its receptor and methods for their identification are also disclosed.
Abstract: IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other hematopoietins in cancer therapies.
Type:
Grant
Filed:
June 17, 1991
Date of Patent:
February 19, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
Steven C. Clark, Gordon G. Wong, Paul Schendel, John McCoy
Abstract: A temperature-sensitive polymer formulation for delivery of osteoinductive proteins is disclosed. The formulation comprises a pharmaceutically acceptable admixture of a temperature sensitive polymer and an osteoinductive protein. The formulations of the present invention enhance the retention of the osteoinductive protein at the site of administration.
Abstract: Purified BMP-11 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the proteins may be useful for the induction and/or maintenance of bone, cartilage and/or other connective tissue, and/or neuronal tissue.
Type:
Grant
Filed:
October 7, 1999
Date of Patent:
January 22, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
Anthony J. Celeste, John M. Wozney, R. Scott Thies
Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Type:
Grant
Filed:
February 25, 2000
Date of Patent:
January 15, 2002
Assignee:
Genetics Institute, Inc.
Inventors:
John Leonard, Samuel Goldman, Richard O'Hara, Jr.
Abstract: Purified BMP-16 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-16 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.
Abstract: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.
Type:
Grant
Filed:
November 2, 1998
Date of Patent:
November 27, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Lih-Ling Lin, Jennifer Chen, Andrea R. Schievella, James Graham
Abstract: A method and apparatus are disclosed for identifying protein-coding regions in a nucleic acid sequence. In order to predict the coding regions within a sequence, a single metric is used without reference or comparison to a predetermined noise level or signal-to-noise ratio. This single metric, periodicity at ⅓, is analyzed using a discrete cosine transformation (DiCTion) function. For each open reading frame or sequence region, a score is generated using the discrete cosine transformation function. Regions within a sequence that have a score above a predetermined threshold are identified as protein-coding regions. The aspects of the invention may also be applied to gather other information from sequences, such as the location of the borders of a putative coding region, within a genomic sequence.
Abstract: Novel IL-1-R intracellular ligand proteins are disclosed. Polynucleotides encoding the IL-1-R intracellular ligand protein are also disclosed, along with vectors, host cells, and methods of making the IL-1-R intracellular ligand protein. Pharmaceutical compositions containing the IL-1-R intracellular ligand protein, methods of treating inflammatory conditions, and methods of inhibiting IL-1-R intracellular domain binding are also disclosed. Methods of identifying inhibitors of IL-1-R intracellular domain binding and inhibitors identified by such methods are also disclosed.
Abstract: Antibodies reactive with a novel homogeneous human cytokine, Natural Killer Stimulatory Factor, (NKSF), NKSF having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.
Type:
Grant
Filed:
June 4, 1999
Date of Patent:
October 9, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Giorgio Trinchieri, Bice Perussia, Steven C. Clark, Gordon G. Wong, Rodney Hewick, Michiko Kobayashi